Exhibit 99.1
NONREIMBURSABLE SPACE ACT AGREEMENT
BETWEEN
THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
LYNDON B. JOHNSON SPACE CENTER
AND
NANOBAC PHARMACEUTICALS, INC.
The LYNDON B. JOHNSON SPACE CENTER (JSC) of the NATIONAL AERONAUTICS AND SPACE
ADMINISTRATION (NASA), herein referred to as JSC or NASA respectively and
NANOBAC PHARMACEUTICALS, INC. (to be renamed Nanobac Life Sciences, Inc.), a
Florida corporation, herein referred to as NANOBAC, desire to enter into a
nonreimbursable Space Act Agreement, herein referred to as Agreement, the
primary objective of which is to collaborate on research into nanobacteria in
the field of healthcare and medicine.
ARTICLE I - INTRODUCTION
NANOBAC is a biolifescience company working to improve human health through the
detection and eradication of Nanobacterium sanguineum (nanobacteria), a novel
pathogen implicated in the formation of disease-causing calcified plaque in the
circulatory system and other vital organs. NANOBAC is developing unique
technologies for early accurate diagnoses of nanobacterial infection, and
eradication methods which will allow physicians to effectively manage the
clinical symptoms of the disease, improve therapeutic results, and as an
outcome, lower overall medical costs. NANOBAC and NASA are interested in
pathological calcium phosphate particles found in diseases such as kidney
stones, prostatitis, and arthritis, which are all conditions that humans become
more prone to after spending time in a zero gravity environment. This
collaboration would provide NASA the opportunity to utilize NANOBAC's diagnostic
and treatment experience in this field to support NASA's exploration goals in
understanding the effects of long-term space travel on humans and provide
NANOBAC the ability to further develop its methods.
Nanobacteria are a unique agent that is approximately the same size and
morphology as the fossil-like structures detected in Mars meteorites by NASA in
1996. Searching for extraterrestrial life will continue on the molecular level
and NANOBAC's work provides a model for studying mineralized organic matters and
experience with isolation of biomarkers from calcified samples.
ARTICLE II - GENERAL PROVISIONS
A. The parties agree that this Agreement shall pertain only to the research
collaboration specified in articles III and IV. The parties agree that
nothing in this Agreement shall be construed to imply an agreement to
contract in the future. It is the intent of both parties that, should
future phases of this cooperative effort materialize, these phases will be
accomplished under separate agreements.
1 of 15
B. JSC and NANOBAC designate the following individuals, respectively, as
points of contact for coordinating, administering, managing, and monitoring
the activities of their respective parties under this Agreement:
Dr. David S. McKay
National Aeronautics and Space Administration
Lyndon B. Johnson Space Center
2101 NASA Road 1
Houston, TX 77058
Mail Code: SA13
E-mail: david.s.mckay@nasa.gov
and
H. Brady Millican
Nanobac Life Sciences, Inc.
2727 West Martin Luther King
Suite 850
Tampa, FL 33607
E-mail: bmillican@nanobaclabs.com
Each party may at any time and from time to time designate in writing additional
or different individuals to serve as points of contact for the indicated
purposes.
C. Except as required by law or in connection with NANOBAC's obligations as a
publicly traded company, neither party shall make any written news/press
public relations statement or similar public disclosure regarding this
Agreement or the activities conducted pursuant to this Agreement without
the prior consent and approval of the other party, which consent and
approval shall not be unreasonably withheld or delayed. A disclosure that
does not materially differ from a disclosure previously approved by the
other party may be made without additional approval.
D. NANOBAC agrees that, for the duration of this Agreement, and while on JSC
premises, its employees, agents, contractors, subcontractors, and principal
investigators shall comply with all laws and applicable regulations,
instructions, and directives, including, but not limited to, those
pertaining to safety and security.
E. It is understood that any commitment of JSC or NANOBAC facilities,
equipment, supplies, and/or services, in furtherance of the objectives of
this Agreement, shall be on a no-cost, mission-noninterference basis,
subject to availability and approval of the parties' management.
Furthermore, while JSC and NANOBAC agree to apply reasonable efforts to
assure that said facilities, equipment, supplies, and/or services, will
function reliably for their intended use or purpose, nothing in this
Agreement shall be construed to imply that JSC or NANOBAC warrants or makes
any representations as to the quality of their performance or operation.
2 of 15
F. Both parties agree to put forth reasonable efforts and to cooperate in good
faith to achieve the objectives of this Agreement. It is mutually agreed,
however, that the services contemplated by this Agreement shall not be
given priority over any other JSC or NANOBAC agreement or program nor be
performed in any manner which interferes with JSC's or NANOBAC's overall
mission.
G. NANOBAC agrees that nothing in this Agreement shall be construed to imply
that NASA endorses or sponsors any NANOBAC product or service resulting
from activities conducted under this Agreement, regardless of the fact that
such product or service may employ NASA-developed technology. With the
limited exception of factually accurate statements of use by, development
by or for, or connection with NASA, NANOBAC agrees to refrain from the use
of the words "National Aeronautics and Space Administration" or the letters
"NASA," or a combination, variation, or colorable imitation thereof
(including the Insignia), either alone or in combination with other words
or letters, in connection with any product or service being offered or made
available to the public in a manner reasonably calculated to convey the
impression that such product or service has the endorsement or sponsorship
of NASA.
H. It is mutually agreed by both parties that there will be no exchange of
funds between JSC and the NANOBAC with regard to activities conducted under
this Agreement.
I. The results of this effort may be published jointly by JSC and NANOBAC
and/or separately by each of the parties herein. In the event that JSC or
NANOBAC publish separately, each party shall acknowledge the effort of the
other party with regard to the performance of activities conducted under
this Agreement. Furthermore, subject to the confidentiality provisions and
other restrictions on disclosure and the intellectual property ownership
provisions included in this Agreement, JSC and NANOBAC agree to share with
each other all experimental data obtained from activities conducted under
this Agreement, prior to publishing such data in open literature.
ARTICLE III - NANOBAC RESPONSIBILITIES
NANOBAC will:
A. Provide equipment, with such specifications as may be jointly agreed upon
by the parties, including a mammalian cell culture incubator; microscope;
and centrifuge, for use in JSC facilities to conduct the work to be done
under this Agreement. NANOBAC will retain ownership of this equipment and
it will be returned to NANOBAC upon termination of this Agreement
B. Provide specialty supplies for nanobacteria research (monoclonal
antibodies, diagnostic kits, chemicals), in such quantities and with such
specifications as may be jointly agreed upon by the parties.
3 of 15
C. Provide a staff scientist as a principal researcher to work with NASA
personnel to conduct the research contemplated under this Agreement.
D. Conduct experiments, currently planned to be, subject to specific agreement
of the parties and review and approval by the JSC Committee for the
Protection of Human Subjects or other appropriate review boards, as
required:
a. Experiments for biological characterization of nanobacteria
i. Nucleic acid detection and sequencing in cultured nanobacteria
b. Definition of unique biomarkers
i. Search for nanobacteria in kidney stones and prostate tissue
using antibody tests and electron microscopy.
ii. Development of new rapid diagnostic methods for detecting trace
amounts of nanobacteria in fluid samples using advanced and
miniaturized ELISA testing techniques and microarray techniques
iii. Development of methods for detecting unique Ca Phosphate and Ca
Carbonate crystallization structures in both human tissue samples
and in lakes, rivers, and similar environments
c. Finding a potential correlation between nanobacteria and pathological
calcification related diseases
d. Nanobacterial growth and antibiotic sensitivity in microgravity and/or
microgravity simulation
i. Culture and growth of nanobacteria under various conditions
including simulated micro gravity in a bioreactor. Effects of
changing environmental conditions will be evaluated.
e. Screening human tissue samples for potential nanobacteria infection
before and after microgravity related missions
f. Application and development of nanobacteria eradication/treatment
methodologies
i. Development of methods for dissolving nanobacteria-produced
calcification structures in human tissue
ii. Development of methods for arresting the growth of and possibly
eliminating nanobacteria in human tissue
g. Development of methods for removing nanobacteria from fluids by
filtering and by contact properties
h. Search for nanobacteria biosignatures in earth fossils and in Mars
meteorites
4 of 15
E. Collect data from the experiments conducted under this Agreement and share
that data with JSC, subject to the confidentiality provisions and other
restrictions on disclosure and the intellectual property ownership
provisions included in this Agreement.
F. When deemed necessary by both parties to meet the requirements of this
Agreement, provide no more than two (2) additional personnel to work with
its scientist. JSC shall have input into the background and training
qualifications required of any proposed personnel.
ARTICLE IV - JSC RESPONSIBILITIES
JSC will:
A. Provide a Bio Safety Level 2 space for a nanobacteria research lab to
conduct the experiments contemplated under this Agreement as well as basic
lab supplies, including but not limited to water bath, autoclave, shakers,
micro-gram sensitive scales, basic micropipettes, lab disposables, lab
coats, lab-glassware, biohazard removal service, refrigerator, and -20c
freezer (see items in Schedule A).
B. Provide appropriate work space at JSC for NANOBAC's personnel located at
JSC to work on the activities contemplated under this Agreement.
C. Collect data from the experiments conducted under this Agreement and share
that data with NANOBAC, subject to the confidentiality provisions and other
restrictions on disclosure and the intellectual property ownership
provisions included in this Agreement.
D. Provide routine safety training, access to basic laboratory services for
nanobacteria science, electron microscopy, molecular biology /
geology-mineralogy research facilities, a computer and computer services,
internet-email, printers, scanners, imaging facilities, etc. for NANOBAC
personnel while operating at JSC.
ARTICLE V - FUNDING
Nothing in this Agreement shall be construed to imply any commitment of JSC's or
NANOBAC's funds or appropriations. In addition, JSC's resource commitments to
the Agreement are subject to availability of appropriated funds, and nothing
herein may be construed as implying that Congress will appropriate funds at a
later date to discharge JSC's obligations hereunder.
ARTICLE VI - LIABILITY OF THE PARTIES
A. Except as provided by paragraph B. of this Article, below, the parties
agree to a no-fault, no-subrogation inter-party waiver of liability under
which each party agrees not to make any claim against the other for the
injury to or death of any person, or for damage to or loss of any property,
attributable to JSC or NANOBAC or their employees, agents, contractors,
5 of 15
subcontractors, or principal investigators, arising as a result of
activities expressly or implicitly covered under this Agreement, whether
such injury, death, damage, or loss is caused by negligence or otherwise.
B. As to third party claims, NANOBAC agrees to indemnify and hold the U.S.
Government and its contractors and subcontractors harmless from any claim,
judgment, or cost arising from the injury to or death of any person, or for
damage to or loss of any property, attributable to NANOBAC or its
employees, agents, contractors, subcontractors, or principal investigators,
arising as a result of activities expressly or implicitly covered under
this Agreement, whether such injury, death, damage, or loss is caused by
negligence or otherwise.
ARTICLE VII - INSURANCE
NANOBAC agrees to procure and thereafter maintain liability insurance with
respect to the performance and time period of this Agreement, and to provide JSC
verification of such insurance. The minimum amount of general aggregate
liability coverage required under this insurance policy shall be five million
dollars ($5,000,000.00). Furthermore, it is agreed by the parties that JSC shall
be named as an additional insured under such insurance policy for all activities
conducted by NANOBAC that are either expressly or implicitly covered under this
Agreement.
ARTICLE VIII - PATENT AND INVENTION RIGHTS
A. Definition: The patent and invention rights set forth herein are applicable
to any employees, contractors or subcontractors, or other entities having a
fiduciary or contractual relationship with NANOBAC that are assigned,
tasked, or contracted with to perform specified NANOBAC activities under
this Agreement.
B. General: Title to inventions made (conceived or first actually reduced to
practice) as a consequence of, or in direct relation to, the performance of
activities under this Agreement will remain with the respective inventing
parties (NANOBAC or NASA), and no patent or invention rights are exchanged
between or granted by such parties under this Agreement except as provided
herein.
C. NASA Inventions: NASA will use reasonable efforts to report inventions made
by NASA employees as a consequence of, or that bear a direct relation to,
the performance of specified NASA activities under this Agreement. Upon
request, NASA will use reasonable efforts to grant NANOBAC, in accordance
with the requirements of 37 CFR Part 404, an exclusive or partially
exclusive, revocable, royalty-bearing license, on terms to be subsequently
negotiated to any NASA invention that may be made under the Agreement and
on which NASA decides to file a patent application. This license will be
subject to the rights reserved in paragraph F. (1), below.
6 of 15
D. NASA Contractor Inventions: In the event NASA contractors are tasked to
perform work in support of specified NASA activities under this Agreement
and inventions are made by contractor employees or jointly between NASA
employees and contractor employees, and NASA has the right to acquire or
has acquired title to such inventions, NASA will use reasonable efforts to
report such inventions. Upon request, NASA will use reasonable efforts to
grant NANOBAC, in accordance with the requirements of 37 CFR Part 404, an
exclusive or partially exclusive, revocable, royalty-bearing license, on
terms to be subsequently negotiated to any NASA invention that may be made
under the Agreement and on which NASA decides to file a patent application.
This license will be subject to the rights reserved in paragraph F. (2),
below. The parties acknowledge that NANOBAC is not a NASA contractor, as
such term is used in this agreement, it being understood that the term
"NASA contractor" refers to a company working with NASA under a contract
entered into pursuant to the Federal Acquisition Regulation (FAR), and not
under a Space Act agreement such as this Agreement.
E. Joint Inventions With NANOBAC: NASA and NANOBAC agree to use reasonable
efforts to identify and report to each other, and to cooperate with each
other in obtaining patent protection on any inventions made jointly between
NASA employees (or employees of NASA contractors) and employees or other
representatives of NANOBAC. Upon timely request, NASA may (1) agree to
refrain from exercising its undivided interest in a manner inconsistent
with NANOBAC's commercial interests, or (2) use reasonable efforts to grant
NANOBAC, in accordance with the requirements of 37 CFR Part 404, an
exclusive or partially exclusive, revocable, royalty-bearing license, on
terms to be subsequently negotiated. Both options (1) and (2) are subject
to the applicable rights reserved in paragraph F., below.
F. Rights to be Reserved in NANOBAC 's License: Any license granted to NANOBAC
pursuant to paragraphs C., D., or E. above will be subject to the
reservation of the following rights:
(1) As to inventions made solely by, or jointly with, NASA employees, the
irrevocable, royalty-free right of the Government of the United States
to practice and have practiced the invention by or on behalf of the
United States and on behalf of any foreign government or international
organization pursuant to any existing or future treaty or agreement
with the United States; provided, however, that NASA shall not
authorize or permit any non-governmental person or entity (other than
NANOBAC) to practice or otherwise exploit any such invention for other
than Federal Governmental purposes.
(2) As to inventions made solely by, or jointly with, employees of NASA
contractors, the rights in the Government of the United States as set
forth in (1) above, as well as the revocable, nonexclusive, royalty
free license in the contractor as set forth in 14 CFR ss. 1245.108.
Notwithstanding anything to the contrary, no contractor of NASA or JSC
shall be given access to any confidential or proprietary material or
information that is the subject of this Agreement without the prior
7 of 15
written consent of NANOBAC, unless such contractor shall have first
acknowledged and agreed to, on terms satisfactory to NANOBAC, the
ownership of such material and information by NANOBAC and the
proprietary and confidential nature thereof.
G. Protection of Reported Inventions: When inventions are reported and
disclosed between the parties in accordance with the provisions of this
clause, the receiving party agrees to withhold such reports or disclosures
from public access for a reasonable time (presumed to be 1 year unless
otherwise mutually agreed) in order to facilitate the allocation and
establishment of the invention and patent rights under these provisions.
H. Patent Filing Responsibilities and Costs: The invention and patent rights
set forth herein shall apply to any patent application filed and patents
obtained in any country, and each party is responsible for its own costs of
preparing, prosecuting, issuing, and maintaining patents covering sole
inventions in any country; except that NASA and NANOBAC may, upon the
reporting of any invention (sole or joint) or in any license granted,
mutually agree otherwise for any country as to patent application
preparation, filing and prosecution responsibilities and costs, and
maintenance responsibilities and costs. As to any invention made jointly
between NASA employees (or employees of a NASA contractor) and employees of
NANOBAC and for which NANOBAC files a patent application, NANOBAC agrees to
include the following statement therein: The invention described herein may
be manufactured and used by or for the U.S. Government for U.S. Government
purposes without the payment of royalties thereon or therefore.
I. Related Inventions: For the purposes of this paragraph, a related invention
is an invention related to the subject matter of this Agreement, but not
made as a consequence of, or in direct relation to, the performance of
activities of the Agreement, and covered by a patent application or patent,
title to which has been assigned or otherwise vested in NASA. NASA will use
reasonable efforts to bring such inventions to the attention of NANOBAC
either prior to, or during the course of this Agreement, and to the extent
such inventions are available for licensing and consistent with the
requirements of 37 CFR Part 404, will enter into negotiations for a
commercial license as contemplated by this Agreement.
ARTICLE IX - RIGHTS IN DATA
A. Definitions: The rights in data set forth herein are applicable to any
employees, contractors or subcontractors, or other entities having a
fiduciary or contractual relationship with NANOBAC that are assigned,
tasked, or contracted with to perform specified NANOBAC activities under
this Agreement. The term "data," as used herein, means recorded
information, regardless of form, the media on which it may be recorded, or
the method of recording. The term includes, but is not limited to, data of
8 of 15
a scientific or technical nature, computer software and documentation
thereof, and data comprising commercial and financial information.
B. General: Data exchanged between NASA and NANOBAC under this Agreement will
be exchanged without restriction as to its disclosure, use, or duplication
except as otherwise marked or as otherwise provided below in this
provision. No preexisting proprietary data will be provided to NANOBAC
under this Agreement unless specifically authorized, in writing, by the
owner of the proprietary data.
C. Background Data: In the event it is necessary for NANOBAC to furnish NASA
with data that existed prior to, or was produced outside of, this
Agreement, and such data embody trade secrets or comprise commercial or
financial information that is privileged or confidential, and such data is
so identified with a suitable notice or legend, the data will be maintained
in confidence and disclosed and used by NASA and its contractors (under
suitable protective conditions) only for the purpose of carrying out NASA's
responsibilities under this Agreement. Upon completion of activities under
this Agreement, such data will be disposed of as requested by NANOBAC.
D. Data Produced by NANOBAC under this Agreement: In the event data first
produced by NANOBAC in carrying out NANOBAC's responsibilities under this
Agreement is furnished to NASA, and NANOBAC considers such data to embody
trade secrets or to comprise commercial or financial information that is
privileged or confidential, and such data is so identified with a suitable
notice or legend, the data will be maintained in confidence and disclosed
and used by NASA and its contractors (under suitable protective conditions)
only for research purposes by or on behalf of NASA.
E. Data First Produced by NASA: As to data first produced by NASA in carrying
out NASA's responsibilities under this Agreement and which data would
embody trade secrets or would comprise commercial or financial information
that is privileged or confidential if it had been obtained from NANOBAC,
such data will, to the extent permitted by law, be appropriately marked
with a notice or legend and maintained in confidence for a period of 5
years after development of the information, with the express understanding
that, during the aforesaid period, such data may be disclosed and used
(under suitable protective conditions) by or on behalf of the Government
for Government purposes only, and thereafter for any purpose whatsoever
without restriction on disclosure and use. NANOBAC agrees not to disclose
such data to any third party without NASA's written approval until the
aforementioned restricted period expires.
F. Data Disclosing an Invention: In the event data exchanged between NASA and
NANOBAC discloses an invention for which patent protection is being
considered, the disclosure and use of such data is not otherwise limited or
restricted herein, and the furnishing party specifically identifies such
data, the receiving party agrees to withhold such data from public
disclosure for a reasonable time (presumed to be 1 year unless mutually
agreed otherwise) in order for patent protection to be obtained.
9 of 15
G. Copyright: In the event data is exchanged with a notice indicating that the
data is protected under copyright, such data will be presumed to be
published and the following paid-up licenses shall apply:
(1) If it is indicated on the data that the data existed prior to, or was
produced outside of, this Agreement, the receiving party and others
acting on its behalf, may reproduce, distribute, and prepare
derivative works for the purpose of carrying out the receiving party's
responsibilities under this Agreement.
(2) If the furnished data does not contain the indication of (1) above, it
will be assumed that the data was first produced under this Agreement,
and the receiving party and others acting on its behalf, may
reproduce, distribute, and prepare derivative works for any of its own
purposes; provided, however, that NASA shall not authorize or permit
any non-governmental person or entity (other than NANOBAC) to practice
or otherwise exploit any such data for other than Federal Governmental
purposes.
H. Oral and visual information: If information that NANOBAC considers to
embody trade secrets or to comprise commercial or financial information
which is privileged or confidential is disclosed orally or visually to
NASA, such information must be reduced to tangible, recorded form (i.e.,
converted into data as defined herein), identified and marked with a
suitable notice or legend as required by paragraphs C. and D. above, and
furnished to NASA within fifteen business days after such oral or visual
disclosure, or NASA shall have no duty to limit or restrict, and shall not
incur any liability for, any disclosure and use of such information.
I. Disclaimer of Liability: Notwithstanding the above, NASA shall not be
restricted in, nor incur any liability for, the disclosure and use of the
following --
(1) Data not identified with a suitable notice or legend as set forth in
paragraphs C. and D.; nor
(2) Information contained in any data for which disclosure and use is
restricted under paragraphs C., D., and E. above, if such information
is or becomes generally known without breach of the above, is known to
or is generated by NASA independently of carrying out responsibilities
under this Agreement, is rightfully received from a third party
without restriction, or is included in data which NANOBAC has, or is
required to furnish to the U.S. Government without restriction on
disclosure and use.
J. Data Subject to Export Control: Technical data, whether or not specifically
identified or marked, that is subject to the export laws and regulations of
the United States and that is provided to NANOBAC under this Agreement will
be treated as such, and will not be further provided to any foreign persons
without proper U.S. Government authorization, where required.
10 of 15
K. Publication of Results: Recognizing that the dissemination of the results
of NASA's activities is one of the considerations for a nonreimbursable
Space Act Agreement, the parties agree to acknowledge NANOBAC as the source
of the materials and material methods in all publications. Each party
agrees that all potential publications arising out of activities related to
this Agreement shall be subject to the consent and approval requirements
under this Agreement. Any review by a party for such purpose may include,
but will not necessarily be limited to, ensuring data accuracy, proper
contributor credit/acknowledgement, determination of most appropriate
journal for submission, protection of patentable subject matter, and
protection of confidential information.
Each party shall provide to the other a copy of any proposed publication or
presentation at least forty-five (45) days in advance of the submission of
such proposed publication or presentation to a journal, editor, or other
third party, except to the extent that the substantive content of such
proposed publication or presentation does not materially differ from what
previously has been approved by the other party. Upon receipt of any such
proposed publication or presentation, the receiving party shall have thirty
(30) days to object in writing to such proposed publication on reasonable
grounds; and, the same shall be deemed approved and consented to unless
objection is received within such period..
ARTICLE X - CONSENT FOR ASSIGNMENT
Neither this Agreement nor any interest arising under it shall be assigned by
NANOBAC or JSC without the express consent of, as to JSC, its Director, Space
and Life Sciences (or such person's successor or designee), or, as to NANOBAC,
its president or any vice president.
ARTICLE XI - APPLICABLE LAW
JSC and NANOBAC agree that U.S. Federal law shall govern this Agreement for all
purposes, including, but not limited to, determining its validity, the meaning
of its provisions, and the rights, obligations and remedies of the parties.
ARTICLE XII - EFFECTIVE DATE, DURATION, AND TERMINATION
This Agreement shall become effective upon the last signature hereto, and will
remain in effect for a period of three (3) years. This Agreement may be
unilaterally terminated by either party upon 30 days written notice, or may be
terminated at any time, upon mutual written agreement of both parties. The
rights and obligations provided in Articles VIII, IX, X, and XI shall survive
the termination of this Agreement.
11 of 15
ARTICLE XIV - AUTHORITY
This Agreement is entered into by the Director of the Space and Life Sciences
Directorate, LYNDON B. JOHNSON SPACE CENTER, NATIONAL AERONAUTICS AND SPACE
ADMINISTRATION, in accordance with authority set forth in Sections 203(c)(5) and
203(c)(6) of the National Aeronautics and Space Act of 1958, as amended, and NPD
1050.1F and redelegation of authority letter, dated November 13, 2001
FOR: NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
/s/ Jeffrey R.Davis September 8, 2004
- ---------------------------------- -------------------------------
Jeffrey R. Davis Date
Director, Space and Life Sciences
Lyndon B. Johnson Space Center
FOR: NANOBAC PHARMACEUTICALS, INC.
/s/ Alex Edwards September 2, 2004
- ---------------------------------- -------------------------------
Alex Edwards Date
Director
12 of 15
SCHEDULE A
Name MSDS/JSC Storage
- -------------------------------- ----------------- ------------------------------------------
DMEM +4oC
Gibco (Cat#11965-092)
Ca-free DMEM +4oC
Gibco (Cat#21068-028)
- -------------------------------- ----------------- ------------------------------------------
L-glutamine 31982 -20oC
FBS -20oC
- -------------------------------- ----------------- ------------------------------------------
BSA 28262 +4oC
PBS tablets +4oC
- -------------------------------- ----------------- ------------------------------------------
HCl 1995 Room temperature (RT), in cabinet for
acid storage
- -------------------------------- ----------------- ------------------------------------------
Glacial acetic acid 42 (RT), in cabinet for acid storage
- -------------------------------- ----------------- ------------------------------------------
Citric acid 950 (RT), in cabinet for acid storage
- -------------------------------- ----------------- ------------------------------------------
Boric acid 624 (RT), in cabinet for acid storage
- -------------------------------- ----------------- ------------------------------------------
NaOH 3658 RT
- -------------------------------- ----------------- ------------------------------------------
Ethanol 8419 RT, in cabinet for flammables
- -------------------------------- ----------------- ------------------------------------------
Methanol 2497 RT, in cabinet for flammables
- -------------------------------- ----------------- ------------------------------------------
2-Merchaptoethanol 12954 +4oC
EDTA solution (1M) 18020 RT
- -------------------------------- ----------------- ------------------------------------------
Coomasie Brillant blue 4671 RT
Glutaraldehyde 35321 +4oC
- -------------------------------- ----------------- ------------------------------------------
Formaldehyde 27599 RT
SDS 3644 RT
- -------------------------------- ----------------- ------------------------------------------
Na2C03 3613 RT
- -------------------------------- ----------------- ------------------------------------------
MgCl2 2389 RT
- -------------------------------- ----------------- ------------------------------------------
KH2PO4 3131 RT
- -------------------------------- ----------------- ------------------------------------------
Na2HPO4 RT
- -------------------------------- ----------------- ------------------------------------------
KCl 3095 RT
NaCl 3634 RT
- -------------------------------- ----------------- ------------------------------------------
Tris-HCl 28347 RT
- -------------------------------- ----------------- ------------------------------------------
Tris base 29755 RT
NaHCO3 3611 RT
- -------------------------------- ----------------- ------------------------------------------
Sodium citrate 3636 RT
- -------------------------------- ----------------- ------------------------------------------
Glycine 1847 RT
- -------------------------------- ----------------- ------------------------------------------
*Nanobacteria detection kits +4oC
(ELISA)
- -------------------------------- ----------------- ------------------------------------------
*Nanobacteria specific -20oC
monoclonal antibodies
- -------------------------------- ----------------- ------------------------------------------
*Nucleic acid isolation kits RT
- -------------------------------- ----------------- ------------------------------------------
*Protein detection kits RT
- -------------------------------- ----------------- ------------------------------------------
13 of 15
Equipments *Mammalian cell culture incubator
--------------------------------------------------
PH meter
Millipore ultra-pure water system
--------------------------------------------------
Timers
Pipet filler
--------------------------------------------------
Shaker
Micropipet sets
--------------------------------------------------
Pipetor
Inverted microscope
--------------------------------------------------
Heating block for eppendorfs
Desicator cabinet
--------------------------------------------------
Vortex
Centrifuge (eppendorf) with cooling system 14000g
--------------------------------------------------
Vacuum pump
Water bath
--------------------------------------------------
Magnetic stirrer with heater
Analytical balances (kg and mg levels)
--------------------------------------------------
Disposables Sterile petri dishes
Culture vessels
--------------------------------------------------
Sterile pipets
Scrapers
--------------------------------------------------
Syringes
Parafilm
--------------------------------------------------
50 ml sterile centrifuge tubes
Glass pipets
--------------------------------------------------
Plastic disposable transfer pipets
Pasteur pipets
--------------------------------------------------
Slides and coverslips
Surgical scalpels
--------------------------------------------------
Gloves
Sterilization filters
--------------------------------------------------
Glass ware Beakers (10, 20, 50, 100, 200, 250, 500, 1000,
2000, 4000 ml)
Thermomiters (digital)
--------------------------------------------------
Flasks
Desicator
--------------------------------------------------
Cylinders in various sizes
Glass bottles (in various sizes)
--------------------------------------------------
Other Color coded autoclavable identification tapes.
--------------------------------------------------
Spatulas
--------------------------------------------------
Various sizes tube racks
--------------------------------------------------
Bulbs for small pipets
--------------------------------------------------
Glass pipet holder (plastic)
--------------------------------------------------
Forceps
Stainless steel lab cart
--------------------------------------------------
14 of 15
--------------------------------------------------
Sprayer bottles
Funnels
--------------------------------------------------
Thermometers
Biohazard autoclave bags
--------------------------------------------------
Autoclave bags
Drop dispensing bottles
--------------------------------------------------
Marking tapes
Scissors
--------------------------------------------------
Whatman papers
--------------------------------------------------
* Nanobac provided
15 of 15